NCT00448136 - A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Neoplasms

Interventions

DRUG

bevacizumab [Avastin]

7.5mg/kg iv on day 1 every 3 weeks

DRUG

5 FU

400mg/m2/day iv on days 1-5 every 6 weeks

DRUG

Streptozotocin

500mg/m2/day iv on days 1-5 every 6 weeks

DRUG

Xeloda

1000mg/m2 po bid on days 1-14 every 3 weeks

Trial Locations (27)

13273

Marseille

13285

Marseille

13385

Marseille

14033

Caen

21079

Dijon

22015

Saint-Brieuc

31059

Toulouse

33075

Bordeaux

34298

Montpellier

37171

Chambray-lès-Tours

44093

Nantes

49933

Angers

51092

Reims

59020

Lille

67091

Strasbourg

69437

Lyon

75571

Paris

75651

Paris

75908

Paris

75970

Paris

76031

Rouen

86021

Poitiers

92104

Boulogne-Billancourt

92118

Clichy

94010

Créteil

94805

Villejuif

06189

Nice

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY